New Survey Reveals Consumer Blind Spot: Ingredient Awareness Is Booming Across Beauty & Wellness — But Consumers Overlook What’s in Their Aesthetic Treatments

NASHVILLE, TN. — September 23, 2025 — From skincare to supplements, Americans are paying closer attention than ever to the ingredients in the products they use. Yet that attentiveness drops when it comes to injectable frown line treatments—despite being one of the most popular aesthetic procedures in the U.S. – leaving many consumers unaware of key differences. New research commissioned by Talker Research on behalf of Revance uncovers a striking knowledge gap in ingredient awareness.  

Revance is working to close that gap through a new educational campaign and landing page where consumers can learn more about what makes DAXXIFY® different as the first and only neurotoxin frown line treatment with a peptide formulation.  

The national survey of 2,000 U.S. adults aged 30–54 revealed that: 

• 91% of respondents are more ingredient-aware today than in the past. 
• 61% of consumers say the top reason they research ingredients is to ensure a product works well, followed by managing allergies (41%) and understanding product differences (36%). 
• 31% of respondents say AI tools have already helped them make smarter ingredient decisions. 

While there is a notable increase in ingredient interest in other categories, a major blind spot remains for frown line treatments: fewer than half could recall any one ingredient in an available neurotoxin treatment on the market, and 53% mistakenly believe all formulations are “more or less the same”— despite significant differences. In fact, most respondents did not recognize that human or animal-based ingredients are common in many treatment formulations. By contrast, DAXXIFY® is the only frown line treatment that has a peptide formulation and does not rely on human or animal-based components to stabilize the active ingredient.¹ 

Among those polled, 36% said they chose their current frown line treatment because it was “the most obvious option,” while another 32% were unaware that alternatives even exist. Encouragingly, 61% said they’d switch to a different frown line treatment based on its ingredients/formula — signaling opportunity for education and awareness in aesthetics that Revance intends to help address. 

“Consumers have become increasingly ingredient-savvy when it comes to what they put on and in their bodies and it’s time that same curiosity extends to aesthetic treatments,” states Jeff Bedard, Founder and CEO of Revance. “Too often, frown line treatments get treated as if they’re all the same, when in reality there are meaningful differences in how they’re formulated. Most people already recognize peptides in skincare and wellness, but few realize there’s a neurotoxin formulated with a peptide. With DAXXIFY®, we’ve introduced the first and only frown line treatment with a peptide formulation giving patients a differentiated option that doesn’t rely on human or animal-based ingredients and raising the bar for transparency across our industry.”

Consumers interested in aesthetic treatments are encouraged to speak with their healthcare provider to learn about the different options available, and to visit the new educational landing page to learn more about DAXXIFY®’s innovative peptide formulation and enter for a chance to win the DAXXIFY® Dream Getaway and treatment. 

Survey Methodology 

Talker Research surveyed 2,000 U.S. adults aged 30–54 who currently receive, or intend to receive within the next six months, a neurotoxin treatment for frown lines. The survey was commissioned by Revance and conducted online between August 5–12, 2025. 

About Revance:  

Revance is a fast-growing, highly acquisitive, global aesthetics and skincare company committed to delivering innovative aesthetics and market-leading skincare solutions across every stage of life. With a differentiated portfolio and market position, Revance meets the evolving needs of patients and consumers worldwide through continued innovation and the commercialization of new products and treatments. Focused on skin science for life, Revance continues to expand its global footprint, with distribution spanning 60 countries and a significant opportunity to enter new markets. 

Revance’s balanced portfolio includes innovative products in the aesthetics space such as DAXXIFY® (daxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers by Teoxane SA, and SkinPen®, an industry-leading microneedling device. RHA® technology is proprietary to and manufactured in Switzerland by Teoxane SA, and Revance is an independent distributor of Teoxane SA to supply the RHA Collection of dermal fillers to the U.S. market. In addition, its consumer skincare portfolio includes leading brands such as PanOxyl®, Blue Lizard®, StriVectin® and BIOJUVE®. 

RHA® is a trademark of TEOXANE SA. 

Learn more at Revance.com, RevanceAesthetics.com, CrownLaboratories.com, and CrownAesthetics.com. Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide. 

Media Contact:  

EvolveMKD 
Revance@EvolveMKD.com 

References:  

1.     DAXXIFY®. Prescribing Information. Revance Therapeutics, Inc; 2023.  

IMPORTANT SAFETY INFORMATION for DAXXIFY® (daxibotulinumtoxinA-Ianm) injection  

DAXXIFY® may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of DAXXIFY®:  

• Problems swallowing, speaking, or breathing due to weakening of associated muscles can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.  

• Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms that include loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.  

Do not receive DAXXIFY® if you are allergic to any of the ingredients in DAXXIFY® (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as rimabotulinumtoxinB (MYOBLOC®), onabotulinumtoxinA (BOTOX®/BOTOX® Cosmetic), abobotulinumtoxinA (DYSPORT®), incobotulinumtoxinA (XEOMIN®) or prabotulinumtoxinA-xvfs (JEUVEAU®); or have a skin infection at the planned injection site. 

DAXXIFY® dosing units are not the same as, or comparable to, any other botulinum toxin product.  

Tell your healthcare provider about all your medical conditions, including any side effects from botulinum toxin products, including dry eye; breathing, swallowing, bleeding, or heart problems; plans to have surgery; weakness of forehead muscles; drooping eyelids; have had surgery on your face; are pregnant or breastfeeding or plan to become pregnant or breastfeed.  

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.  

Using DAXXIFY® with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your healthcare provider that you have received DAXXIFY® in the past.  

Especially tell your healthcare provider if you have received any other botulinum toxin product in the last 4 months or any in the past, and exactly which product you received (such as BOTOX®, BOTOX® Cosmetic, MYOBLOC®, DYSPORT®, XEOMIN®, or JEUVEAU®). DAXXIFY® may cause serious side effects, including allergic reactions (such as itching, rash, redness, swelling, wheezing, trouble breathing, or dizziness or feeling faint), heart problems (such as irregular heartbeat and heart attack), and eye problems (including dry eye, reduced blinking, and corneal problems). Tell your healthcare provider or get medical help right away if you experience a serious side effect. No serious adverse events of distant spread of toxin effect associated with dermatologic use of DAXXIFY® have been reported in clinical studies at the dose of 40 Units for glabellar lines. The most common side effects of DAXXIFY® include headache, eyelid drooping, and loss of ability to move the muscles in your face.  

These are not all the possible side effects of DAXXIFY®. For more information, see the full Prescribing Information including Boxed Warning, and refer to the Medication Guide or talk with your doctor. To report side effects associated with DAXXIFY®, please call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.  

APPROVED USE  
DAXXIFY® is a prescription medicine that is injected into muscles and used in adults to temporarily improve the look of moderate to severe frown lines between the eyebrows. 

DAXI-001723.2 

###